Bivalent inhibition of human beta-tryptase

Schaschke N, Matschiner G, Zettl F, Marquardt U, Bergner A, Bode W, Sommerhoff CP, Moroder L (2001)
CHEMISTRY & BIOLOGY 8(4): 313-327.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Schaschke, NorbertUniBi; Matschiner, G; Zettl, F; Marquardt, U; Bergner, A; Bode, W; Sommerhoff, CP; Moroder, L
Page URI


Schaschke N, Matschiner G, Zettl F, et al. Bivalent inhibition of human beta-tryptase. CHEMISTRY & BIOLOGY. 2001;8(4):313-327.
Schaschke, N., Matschiner, G., Zettl, F., Marquardt, U., Bergner, A., Bode, W., Sommerhoff, C. P., et al. (2001). Bivalent inhibition of human beta-tryptase. CHEMISTRY & BIOLOGY, 8(4), 313-327.
Schaschke, Norbert, Matschiner, G, Zettl, F, Marquardt, U, Bergner, A, Bode, W, Sommerhoff, CP, and Moroder, L. 2001. “Bivalent inhibition of human beta-tryptase”. CHEMISTRY & BIOLOGY 8 (4): 313-327.
Schaschke, N., Matschiner, G., Zettl, F., Marquardt, U., Bergner, A., Bode, W., Sommerhoff, C. P., and Moroder, L. (2001). Bivalent inhibition of human beta-tryptase. CHEMISTRY & BIOLOGY 8, 313-327.
Schaschke, N., et al., 2001. Bivalent inhibition of human beta-tryptase. CHEMISTRY & BIOLOGY, 8(4), p 313-327.
N. Schaschke, et al., “Bivalent inhibition of human beta-tryptase”, CHEMISTRY & BIOLOGY, vol. 8, 2001, pp. 313-327.
Schaschke, N., Matschiner, G., Zettl, F., Marquardt, U., Bergner, A., Bode, W., Sommerhoff, C.P., Moroder, L.: Bivalent inhibition of human beta-tryptase. CHEMISTRY & BIOLOGY. 8, 313-327 (2001).
Schaschke, Norbert, Matschiner, G, Zettl, F, Marquardt, U, Bergner, A, Bode, W, Sommerhoff, CP, and Moroder, L. “Bivalent inhibition of human beta-tryptase”. CHEMISTRY & BIOLOGY 8.4 (2001): 313-327.

27 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Human Mast Cell Tryptase Is a Potential Treatment for Snakebite Envenoming Across Multiple Snake Species.
Anderson E, Stavenhagen K, Kolarich D, Sommerhoff CP, Maurer M, Metz M., Front Immunol 9(), 2018
PMID: 30038613
Iminosugar-Cyclopeptoid Conjugates Raise Multivalent Effect in Glycosidase Inhibition at Unprecedented High Levels.
Lepage ML, Schneider JP, Bodlenner A, Meli A, De Riccardis F, Schmitt M, Tarnus C, Nguyen-Huynh NT, Francois YN, Leize-Wagner E, Birck C, Cousido-Siah A, Podjarny A, Izzo I, Compain P., Chemistry 22(15), 2016
PMID: 26917097
Emerging trends in enzyme inhibition by multivalent nanoconstructs.
Kanfar N, Bartolami E, Zelli R, Marra A, Winum JY, Ulrich S, Dumy P., Org Biomol Chem 13(39), 2015
PMID: 26338715
A new approach to inhibit human β-tryptase by protein surface binding of four-armed peptide ligands with two different sets of arms.
Jiang QQ, Bartsch L, Sicking W, Wich PR, Heider D, Hoffmann D, Schmuck C., Org Biomol Chem 11(10), 2013
PMID: 23358683
Tryptogalinin is a tick Kunitz serine protease inhibitor with a unique intrinsic disorder.
Valdés JJ, Schwarz A, Cabeza de Vaca I, Calvo E, Pedra JH, Guallar V, Kotsyfakis M., PLoS One 8(5), 2013
PMID: 23658744
Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase beta.
Sommerhoff CP, Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Diederichsen U, Kolmar H., J Mol Biol 395(1), 2010
PMID: 19852971
Multivalent Antimicrobial Peptides as Therapeutics: Design Principles and Structural Diversities.
Liu SP, Zhou L, Lakshminarayanan R, Beuerman RW., Int J Pept Res Ther 16(3), 2010
PMID: 20835389
Protease-activated receptor 2 mediates the proinflammatory effects of synovial mast cells.
Palmer HS, Kelso EB, Lockhart JC, Sommerhoff CP, Plevin R, Goh FG, Ferrell WR., Arthritis Rheum 56(11), 2007
PMID: 17968878
X-ray structures of free and leupeptin-complexed human alphaI-tryptase mutants: indication for an alpha-->beta-tryptase transition.
Rohr KB, Selwood T, Marquardt U, Huber R, Schechter NM, Bode W, Than ME., J Mol Biol 357(1), 2006
PMID: 16414069
Biology of mast cell tryptase. An inflammatory mediator.
Hallgren J, Pejler G., FEBS J 273(9), 2006
PMID: 16640553
Romping the cellular landscape: linear scaffolds for molecular recognition.
Lee Y, Sampson NS., Curr Opin Struct Biol 16(4), 2006
PMID: 16781140
Affinity chromatography of tryptases: design, synthesis and characterization of a novel matrix-bound bivalent inhibitor.
Schaschke N, Gabrijelcic-Geiger D, Dominik A, Sommerhoff CP., Chembiochem 6(1), 2005
PMID: 15593113
Carbohydrates in peptide and protein design.
Jensen KJ, Brask J., Biopolymers 80(6), 2005
PMID: 15929028
Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human beta-tryptase.
Vaz RJ, Gao Z, Pribish J, Chen X, Levell J, Davis L, Albert E, Brollo M, Ugolini A, Cramer DM, Cairns J, Sides K, Liu F, Kwong J, Kang J, Rebello S, Elliot M, Lim H, Chellaraj V, Singleton RW, Li Y., Bioorg Med Chem Lett 14(24), 2004
PMID: 15546728
Hitting multiple targets with multimeric ligands.
Handl HL, Vagner J, Han H, Mash E, Hruby VJ, Gillies RJ., Expert Opin Ther Targets 8(6), 2004
PMID: 15584863
Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor.
Selwood T, Elrod KC, Schechter NM., Biol Chem 384(12), 2003
PMID: 14719803
Bivalent inhibition of beta-tryptase: distance scan of neighboring subunits by dibasic inhibitors.
Schaschke N, Dominik A, Matschiner G, Sommerhoff CP., Bioorg Med Chem Lett 12(6), 2002
PMID: 11959009
The crystal structure of human alpha1-tryptase reveals a blocked substrate-binding region.
Marquardt U, Zettl F, Huber R, Bode W, Sommerhoff C., J Mol Biol 321(3), 2002
PMID: 12162961

59 References

Daten bereitgestellt von Europe PubMed Central.

Polyvalent interactions in biological systems – Implications for design and use of multivalent ligands and inhibitors
Mammen, Angew. Chem. Int. Ed. Engl. 37(), 1998
Strength in numbers: non-natural polyvalent carbohydrate derivatives.
Kiessling LL, Pohl NL., Chem. Biol. 3(2), 1996
PMID: 8807830
Carbohydrate-protein interactions: basis of glycobiology
Lee, Acc. Chem. Res. 28(), 1995
Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus
Spaltenstein, J. Am. Chem. Soc. 113(), 1991
Ligand recognition by influenza virus. The binding of bivalent sialosides.
Glick GD, Toogood PL, Wiley DC, Skehel JJ, Knowles JR., J. Biol. Chem. 266(35), 1991
PMID: 1748643
High-affinity pentavalent ligands of Escherichia coli heat-labile enterotoxin by modular structure-based design
Fan, J. Am. Chem. Soc. 122(), 2000
A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers.
Cheronis JC, Whalley ET, Nguyen KT, Eubanks SR, Allen LG, Duggan MJ, Loy SD, Bonham KA, Blodgett JK., J. Med. Chem. 35(9), 1992
PMID: 1578482
Bivalent inhibitors of protein tyrosine kinases
Profit, J. Am. Chem. Soc. 121(), 1999
Anticoagulatory substances of bloodsucking animals – from hirudin to hirudin mimetics
Dodt, Angew. Chem. Int. Ed. Engl. 34(), 1995
Design and evaluation of novel bivalent thrombin inhibitors based on amidinophenylalanines.
Steinmetzer T, Renatus M, Kunzel S, Eichinger A, Bode W, Wikstrom P, Hauptmann J, Sturzebecher J., Eur. J. Biochem. 265(2), 1999
PMID: 10504391
The influence of polyvalency on the binding properties of antibodies.
Crothers DM, Metzger H., Immunochemistry 9(3), 1972
PMID: 4113719
Evaluation of group contributions to ligand binding.
Rappaport HP., J. Theor. Biol. 79(2), 1979
PMID: 513806
On the attribution and additivity of binding energies.
Jencks WP., Proc. Natl. Acad. Sci. U.S.A. 78(7), 1981
PMID: 16593049
A trivalent system from vancomycin.D-ala-D-Ala with higher affinity than avidin.biotin.
Rao J, Lahiri J, Isaacs L, Weis RM, Whitesides GM., Science 280(5364), 1998
PMID: 9563940
Design, synthesis, and characterization of a high-affinity trivalent system derived from vancomycin and L-Lys-D-Ala-D-Ala
Rao, J. Am. Chem. Soc. 122(), 2000
The structure of a complex of recombinant hirudin and human alpha-thrombin.
Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW 2nd., Science 249(4966), 1990
PMID: 2374926
Structure of 20S proteasome from yeast at 2.4 A resolution.
Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R., Nature 386(6624), 1997
PMID: 9087403
Human beta-tryptase is a ring-like tetramer with active sites facing a central pore.
Pereira PJ, Bergner A, Macedo-Ribeiro S, Huber R, Matschiner G, Fritz H, Sommerhoff CP, Bode W., Nature 392(6673), 1998
PMID: 9521329
The structure of the human betaII-tryptase tetramer: fo(u)r better or worse.
Sommerhoff CP, Bode W, Pereira PJ, Stubbs MT, Sturzebecher J, Piechottka GP, Matschiner G, Bergner A., Proc. Natl. Acad. Sci. U.S.A. 96(20), 1999
PMID: 10500112
Bivalency as a principle for proteasome inhibition.
Loidl G, Groll M, Musiol HJ, Huber R, Moroder L., Proc. Natl. Acad. Sci. U.S.A. 96(10), 1999
PMID: 10318898
Synthesis of bivalent inhibitors of eucaryotic proteasomes
Loidl, J. Peptide Sci. 6(), 2000
The human mast cell tryptase tetramer: a fascinating riddle solved by structure.
Sommerhoff CP, Bode W, Matschiner G, Bergner A, Fritz H., Biochim. Biophys. Acta 1477(1-2), 2000
PMID: 10708850
Cyclodextrins as templates for the presentation of protease inhibitors.
Schaschke N, Musiol HJ, Assfalg-Machleidt I, Machleidt W, Rudolph-Bohner S, Moroder L., FEBS Lett. 391(3), 1996
PMID: 8764993
Cyclodextrin as carrier of peptide hormones. Conformational and biological properties of β-cyclodextrin/gastrin constructs
Schaschke, J. Am. Chem. Soc. 120(), 1998
Beta-cyclodextrin/epoxysuccinyl peptide conjugates: a new drug targeting system for tumor cells.
Schaschke N, Assfalg-Machleidt I, Machleidt W, Lassleben T, Sommerhoff CP, Moroder L., Bioorg. Med. Chem. Lett. 10(7), 2000
PMID: 10762052
Characterization of regiospecific A,C- and A,D-disulfonate capping of β-cyclodextrin. Capping as an efficient production technique
Tabushi, J. Am. Chem. Soc. 106(), 1984
PyBOP®: a new peptide coupling reagent devoid of toxic by-product
Coste, Tetrahedron Lett. 31(), 1990
Regulation of the activity of secreted human lung mast cell tryptase by mast cell proteoglycans.
Lindstedt KA, Kokkonen JO, Kovanen PT., Biochim. Biophys. Acta 1425(3), 1998
PMID: 9838225
Structural basis of the activation and action of trypsin
Huber, Acc. Chem. Res. 11(), 1978

Contributions of tryptophan side chains to the circular dichroism of globular proteins: Exciton couplets and coupled oscillators
Grishina, Faraday Discuss. 99(), 1994
Structural changes associated with the spontaneous inactivation of the serine proteinase human tryptase.
Schechter NM, Eng GY, Selwood T, McCaslin DR., Biochemistry 34(33), 1995
PMID: 7654717

Of mites and men: trypsin-like proteases in the lungs.
Caughey GH., Am. J. Respir. Cell Mol. Biol. 16(6), 1997
PMID: 9191463
Mast cell tryptase potentiates histamine-induced contraction in human sensitized bronchus.
Johnson PR, Ammit AJ, Carlin SM, Armour CL, Caughey GH, Black JL., Eur. Respir. J. 10(1), 1997
PMID: 9032489
Inhibitors of tryptase for the treatment of mast cell-mediated diseases.
Rice KD, Tanaka RD, Katz BA, Numerof RP, Moore WR., Curr. Pharm. Des. 4(5), 1998
PMID: 10197050
Quantitative locus analysis of airway hyperresponsiveness in A/J and C75BL/6J mice
De, Nature Genet. 11(), 1995
Natural disruption of the mouse mast cell protease 7 gene in the C57BL/6 mouse.
Hunt JE, Stevens RL, Austen KF, Zhang J, Xia Z, Ghildyal N., J. Biol. Chem. 271(5), 1996
PMID: 8576265
Inhibition of human mast cell tryptase by benzamidine derivatives.
Sturzebecher J, Prasa D, Sommerhoff CP., Biol. Chem. Hoppe-Seyler 373(10), 1992
PMID: 1418674
Bis(5-amidino-2-benzimidazolyl)methane and related amidines are potent, reversible inhibitors of mast cell tryptases.
Caughey GH, Raymond WW, Bacci E, Lombardy RJ, Tidwell RR., J. Pharmacol. Exp. Ther. 264(2), 1993
PMID: 8437115
Potent selective nonpeptidic inhibitors of human lung tryptase.
Burgess LE, Newhouse BJ, Ibrahim P, Rizzi J, Kashem MA, Hartman A, Brandhuber BJ, Wright CD, Thomson DS, Vigers GP, Koch K., Proc. Natl. Acad. Sci. U.S.A. 96(15), 1999
PMID: 10411878
Syntheses and evaluation of amidinobenzofuran derivatives as tryptase inhibitors.
Ono S, Kuwahara S, Takeuchi M, Sakashita H, Naito Y, Kondo T., Bioorg. Med. Chem. Lett. 9(23), 1999
PMID: 10612586
Dibasic inhibitors of human mast cell tryptase. Part 1: synthesis and optimization of a novel class of inhibitors.
Rice KD, Gangloff AR, Kuo EY, Dener JM, Wang VR, Lum R, Newcomb WS, Havel C, Putnam D, Cregar L, Wong M, Warne RL., Bioorg. Med. Chem. Lett. 10(20), 2000
PMID: 11055355
Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity.
Rice KD, Wang VR, Gangloff AR, Kuo EY, Dener JM, Newcomb WS, Young WB, Putnam D, Cregar L, Wong M, Simpson PJ., Bioorg. Med. Chem. Lett. 10(20), 2000
PMID: 11055356
A Kazal-type inhibitor of human mast cell tryptase: isolation from the medical leech Hirudo medicinalis, characterization, and sequence analysis.
Sommerhoff CP, Sollner C, Mentele R, Piechottka GP, Auerswald EA, Fritz H., Biol. Chem. Hoppe-Seyler 375(10), 1994
PMID: 7888081

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

PMID: 11325588
PubMed | Europe PMC

Suchen in

Google Scholar